{"id":4238,"date":"2021-10-04T10:05:47","date_gmt":"2021-10-04T08:05:47","guid":{"rendered":"http:\/\/www.lvsada.lv\/?p=4238"},"modified":"2021-10-04T10:06:33","modified_gmt":"2021-10-04T08:06:33","slug":"4238","status":"publish","type":"post","link":"https:\/\/www.lvsada.lv\/?p=4238","title":{"rendered":"30.09. Preses rel\u012bze"},"content":{"rendered":"

Inform\u0101cija pla\u0161sazi\u0146as l\u012bdzek\u013ciem<\/strong><\/span><\/p>\n

\u00a0 \u00a0Latvijas Vesel\u012bbas un soci\u0101l\u0101s apr\u016bpes darbinieku arodbiedr\u012bba (LVSADA) v\u0113r\u0161 sabiedr\u012bbas uzman\u012bbu uz to, ka vald\u012bba, 28. septembr\u012b nosakot vakcin\u0113\u0161anos pret Covid-19 par oblig\u0101tu vair\u0101k\u0101s darbinieku grup\u0101s, nav skaidri noteikusi valsts atbild\u012bbu un atbalstu gad\u012bjum\u0101, ja darbiniekam n\u0101ktos ciest no vakcin\u0101cijas blakn\u0113m.<\/strong><\/span><\/p>\n

\u00a0 \u00a0Atbilsto\u0161i jaun\u0101kajiem Eiropas Z\u0101\u013cu a\u0123ent\u016bras (European Medicines Agency) datiem (https:\/\/www.ema.europa.eu<\/a>), starp nopietn\u0101m Covid-19 vakc\u012bnu blakn\u0113m, kas sastopamas reti vai \u013coti reti, ir ak\u016bta perif\u0113ra sejas paral\u012bze, sejas t\u016bska, tromboze ar trombocitop\u0113niju un Guillain-Barr\u00e9 sindroms. T\u0101du nopietnu blak\u0146u k\u0101 anafilakse, miokard\u012bts, perikard\u012bts, rokas t\u016bska un kapil\u0101ru caurlaid\u012bbas sindroms sastopam\u012bba v\u0113l tiek p\u0113t\u012bta. Vis\u0101m Latvij\u0101 lietotaj\u0101m vakc\u012bn\u0101m ir tirdzniec\u012bbas at\u013cauja ar nosac\u012bjumiem, kas paredz papildus monitor\u0113\u0161anu.<\/span><\/p>\n

\u00a0 \u00a0Ne velti viens no Eiropas Padomes Parlament\u0101r\u0101s asamblejas 27.01.2021. rezol\u016bcijas Nr. 2361 (par Covid-19 vakcin\u0101cijas \u0113tiskajiem, juridiskajiem un praktiskajiem apsv\u0113rumiem) punktiem paredz, ka valst\u012bm j\u0101nodro\u0161ina pien\u0101c\u012bga kompens\u0101cija par kait\u0113jumu, kas radies personai vakcin\u0101cijas d\u0113\u013c. Viens no asamblejas galvenajiem m\u0113r\u0137iem ir veicin\u0101t un aizsarg\u0101t cilv\u0113kties\u012bbas un tiesiskumu vis\u0101s Eiropas valst\u012bs (https:\/\/www.saeima.lv<\/a>).<\/span><\/p>\n

\u00a0 \u00a0Slov\u0113nijas vald\u012bba vakar, 29. septembr\u012b ir uz laiku aptur\u0113jusi vakcin\u0101ciju ar vienu no vakc\u012bn\u0101m, jo tiek izmekl\u0113ti divi<\/u> aizdom\u012bgi n\u0101ves gad\u012bjumi, ko var\u0113tu b\u016bt izrais\u012bjusi vakc\u012bna (http:\/\/www.tvnet.lv<\/a>; http:\/\/www.msn.com<\/a>). Latvij\u0101 patlaban tiek izmekl\u0113ti vienpadsmit<\/u> l\u012bdz\u012bga rakstura gad\u012bjumi, ta\u010du vald\u012bba ar dro\u0161u roku nosaka vakcin\u0101ciju par oblig\u0101tu bez skaidr\u0101m dro\u0161\u012bbas garantij\u0101m!<\/span><\/p>\n

\u00a0 \u00a0LVSADA priek\u0161s\u0113d\u0113t\u0101js Valdis Keris secina: \u201cVai nu vald\u012bba jau iepriek\u0161 ir stingri p\u0101rliecin\u0101ta par izmekl\u0113\u0161anas rezult\u0101tiem, vai ar\u012b klaji ignor\u0113 nepiecie\u0161am\u012bbu uz\u0146emties atbild\u012bbu par savu l\u0113mumu sek\u0101m. Abos gad\u012bjumos ir viela nopietn\u0101m p\u0101rdom\u0101m.\u201d <\/strong><\/span><\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong><\/span><\/p>\n

Inform\u0101ciju sagatavoja LVSADA biroja administratore Vita Plu\u0161a (tel. 67847300).<\/span><\/p>\n

2021. gada 30. septembr\u012b<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Inform\u0101cija pla\u0161sazi\u0146as l\u012bdzek\u013ciem \u00a0 \u00a0Latvijas Vesel\u012bbas un soci\u0101l\u0101s apr\u016bpes darbinieku arodbiedr\u012bba (LVSADA) v\u0113r\u0161 sabiedr\u012bbas uzman\u012bbu uz to, ka vald\u012bba, 28. septembr\u012b nosakot vakcin\u0113\u0161anos pret Covid-19 par oblig\u0101tu vair\u0101k\u0101s darbinieku grup\u0101s, nav skaidri noteikusi valsts atbild\u012bbu un atbalstu gad\u012bjum\u0101, ja darbiniekam n\u0101ktos ciest no vakcin\u0101cijas blakn\u0113m. \u00a0 \u00a0Atbilsto\u0161i jaun\u0101kajiem Eiropas Z\u0101\u013cu a\u0123ent\u016bras (European Medicines Agency) datiem…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-4238","post","type-post","status-publish","format-standard","hentry","category-4"],"_links":{"self":[{"href":"https:\/\/www.lvsada.lv\/index.php?rest_route=\/wp\/v2\/posts\/4238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lvsada.lv\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lvsada.lv\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lvsada.lv\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lvsada.lv\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4238"}],"version-history":[{"count":4,"href":"https:\/\/www.lvsada.lv\/index.php?rest_route=\/wp\/v2\/posts\/4238\/revisions"}],"predecessor-version":[{"id":4242,"href":"https:\/\/www.lvsada.lv\/index.php?rest_route=\/wp\/v2\/posts\/4238\/revisions\/4242"}],"wp:attachment":[{"href":"https:\/\/www.lvsada.lv\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lvsada.lv\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lvsada.lv\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}